NAVIGATE Study

The NAVIGATE Study investigated whether a medication called VX-445, combined with other drugs, could improve lung function and reduce symptoms in people with cystic fibrosis caused by specific genetic mutations. It was a clinical trial involving patients who still had some functioning lung tissue. The study aimed to determine if this combination therapy could enhance respiratory health and quality of life by addressing the underlying genetic defect. Overall, it sought to evaluate the safety and effectiveness of this targeted treatment approach for cystic fibrosis patients with certain mutations.